Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$19.42

-0.47 (-2.36%)

04:55
08/16/18
08/16
04:55
08/16/18
04:55

Exelixis management to meet with Oppenheimer

Meeting to be held in San Francisco on August 16 hosted by Oppenheimer.

  • 16

    Aug

  • 12

    Sep

  • 14

    Jan

EXEL Exelixis
$19.42

-0.47 (-2.36%)

05/10/18
PIPR
05/10/18
NO CHANGE
Target $29
PIPR
Overweight
Exelixis price target lowered to $29 from $33 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Exelixis (EXEL) to $29 from $33 after partner Roche (RHHBY) reported the Phase 3 IMblaze370 trial in microsatellite stable colorectal cancer patients did not meet its overall survival primary endpoint. However, the data do not impact two ongoing Phase 3 trials of cobimetinib and Tecentriq in BRAF-mutant melanoma, said Tenthoff, who keeps an Overweight rating on Exelixis shares.
05/23/18
RBCM
05/23/18
NO CHANGE
RBCM
Exelixis shares defended at RBC Capital
05/23/18
RBCM
05/23/18
NO CHANGE
RBCM
Exelixis pullback today a buying opportunity, says RBC Capital
RBC Capital analyst Kennen MacKay attributes the selloff today in shares of Exelixis to April total prescription data from Symphony. The analyst notes, however, that his analysis indicates the Symphony totals for April are well below those of IMS, implying prescription declines from March to April are not seen in IMS data. While the flat month-to-month growth from may be viewed as concerning for Cabo's continued uptake in first-line renal cell carcinoma post approval and launch of competitor Opdivo plus Yervoy in mid-April, March represented an "especially strong month," MacKay tells investors in a research note. He remains a buyer of Exelixis shares on today's weakness.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $29
PIPR
Overweight
Exelixis recent weakness a buying opportunity, says Piper Jaffray
After surveying 26 medical oncologists who treat metastatic renal cell carcinoma to gauge the use of Cabometyx and immuno-oncology agents, Piper Jaffray analyst Edward Tenthoff recommends using the recent weakness in shares of Exelixis as a buying opportunity. Not surprisingly, 92% of respondents plan to begin prescribing Opdivo plus Yervoy since approval in April, Tenthoff tells investors in a research note. The analyst, however, is encouraged that 92% of the oncologists surveyed also plan to maintain or increase Cabometyx use in the first-line representing growth opportunity. In addition, Cabometyx is clearly the tyrosine kinase inhibitor of choice in the second-line, the analyst adds. He reiterates an Overweight rating on Exelixis with a $29 price target. Tenthoff believes the survey supports his 2018 Cabometyx sales forecast of $538M.

TODAY'S FREE FLY STORIES

LXFR

Luxfer

$21.42

-1.26 (-5.56%)

06:00
12/18/18
12/18
06:00
12/18/18
06:00
Hot Stocks
Breaking Hot Stocks news story on Luxfer »

Luxfer to acquire Neo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRO

Adecogro

$6.69

-0.35 (-4.97%)

06:00
12/18/18
12/18
06:00
12/18/18
06:00
Initiation
Adecogro initiated  »

Adecogro initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.30

-17.39 (-4.76%)

05:59
12/18/18
12/18
05:59
12/18/18
05:59
Periodicals
Musk's Boring Co. faces concerns over diversion of SpaceX resources, WSJ says »

Elon Musk's the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$129.11

-3.75 (-2.82%)

05:59
12/18/18
12/18
05:59
12/18/18
05:59
Periodicals
J&J looks to contain fallout from baby powder report with ads, Reuters reports »

Johnson & Johnson on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 27

    Jan

EFX

Equifax

$97.25

0.06 (0.06%)

05:55
12/18/18
12/18
05:55
12/18/18
05:55
Conference/Events
Equifax to meet with investors »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

UNCFF

UniCredit

$0.00

(0.00%)

05:53
12/18/18
12/18
05:53
12/18/18
05:53
Hot Stocks
Italy's UniCredit settles dispute with Caius »

On August 6, UniCredit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLC

Taiwan Liposome

$6.01

(0.00%)

05:52
12/18/18
12/18
05:52
12/18/18
05:52
Hot Stocks
Taiwan Liposome announces full enrollment of TLC590 Phase I/II clinical trial »

Taiwan Liposome announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$207.01

-8.57 (-3.98%)

, INGN

Inogen

$125.96

-4.85 (-3.71%)

05:48
12/18/18
12/18
05:48
12/18/18
05:48
Recommendations
Align Technology, Inogen, Nuvectra, Intuitive Surgical, Merit Medical analyst commentary  »

Piper lays out top…

ALGN

Align Technology

$207.01

-8.57 (-3.98%)

INGN

Inogen

$125.96

-4.85 (-3.71%)

NVTR

Nuvectra

$16.27

-0.38 (-2.28%)

ISRG

Intuitive Surgical

$481.95

-9.89 (-2.01%)

MMSI

Merit Medical

$54.54

-1.79 (-3.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

ACHV

Achieve Life Sciences

$1.37

-0.07 (-4.86%)

05:45
12/18/18
12/18
05:45
12/18/18
05:45
Hot Stocks
Achieve Life Sciences: FDA confirms agreement with Initial Pediatric Study Plan »

Achieve Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MANU

Manchester United

$17.30

-0.2 (-1.14%)

05:39
12/18/18
12/18
05:39
12/18/18
05:39
Hot Stocks
Manchester United announces departure of manager Jose Mourinho »

Manchester United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$255.12

-5.49 (-2.11%)

05:39
12/18/18
12/18
05:39
12/18/18
05:39
Periodicals
Ex-official thinks U.S., China can reach trade deal in 90 days, SCMP reports »

Zhu Min, who was deputy…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$255.12

-5.49 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$44.31

-1 (-2.21%)

05:38
12/18/18
12/18
05:38
12/18/18
05:38
Hot Stocks
Magna acquires VIZA Geca, terms not disclosed »

Magna signed an agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYB

RYB Education

$6.05

-0.08 (-1.31%)

05:36
12/18/18
12/18
05:36
12/18/18
05:36
Hot Stocks
RYB Education announces $12M share repurchase program »

RYB Education announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$45.72

-0.9 (-1.93%)

05:32
12/18/18
12/18
05:32
12/18/18
05:32
Recommendations
Oracle analyst commentary  »

Oracle Q2 results a step…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDAQ

Nasdaq

$85.19

-1.3 (-1.50%)

05:30
12/18/18
12/18
05:30
12/18/18
05:30
Hot Stocks
Nasdaq raises offer for proposed acquisition of Cinnober to SEK 87 per share »

On September 14, Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRH

DiamondRock

$9.58

-0.33 (-3.33%)

05:27
12/18/18
12/18
05:27
12/18/18
05:27
Downgrade
DiamondRock rating change  »

DiamondRock downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YNDX

Yandex

$27.49

-0.52 (-1.86%)

05:27
12/18/18
12/18
05:27
12/18/18
05:27
Hot Stocks
Yandex to acquire property site for new Moscow headquarters »

Yandex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHO

Sunstone Hotel

$14.08

-0.32 (-2.22%)

05:23
12/18/18
12/18
05:23
12/18/18
05:23
Downgrade
Sunstone Hotel rating change  »

Sunstone Hotel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HST

Host Hotels

$17.31

-0.46 (-2.59%)

05:21
12/18/18
12/18
05:21
12/18/18
05:21
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$64.86

-0.78 (-1.19%)

, S

Sprint

$5.83

-0.14 (-2.35%)

05:18
12/18/18
12/18
05:18
12/18/18
05:18
Hot Stocks
T-Mobile, Sprint receives approval from CFIUS, Team Telecom »

T-Mobile (TMUS) and…

TMUS

T-Mobile

$64.86

-0.78 (-1.19%)

S

Sprint

$5.83

-0.14 (-2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPG

Washington Prime

$5.76

-0.38 (-6.19%)

05:18
12/18/18
12/18
05:18
12/18/18
05:18
Downgrade
Washington Prime rating change  »

Washington Prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$39.62

-0.76 (-1.88%)

05:16
12/18/18
12/18
05:16
12/18/18
05:16
Downgrade
Fortune Brands rating change  »

Fortune Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:15
12/18/18
12/18
05:15
12/18/18
05:15
General news
FX Action: USD-JPY extended losses »

FX Action: USD-JPY…

SNDR

Schneider National

$19.12

-0.015 (-0.08%)

05:11
12/18/18
12/18
05:11
12/18/18
05:11
Downgrade
Schneider National rating change  »

Schneider National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSC

Norfolk Southern

$147.63

-3.18 (-2.11%)

05:11
12/18/18
12/18
05:11
12/18/18
05:11
Upgrade
Norfolk Southern rating change  »

Norfolk Southern upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.